Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine in Binge-eating Symptoms
NCT04181957Terminated
- Sponsor
- University of Birmingham
- Start
- May 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of lisdexamfetamine in binge eating disorder (BED), sponsored by University of Birmingham. Primary endpoints: Metabolic food intake at 15 minutes and Hedonic food intake at 15 minutes. Started May 2019; status: terminated.
02
Drugs
lisdexamfetamine
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT04181957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04181957.